N/A N=4 Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus
Nephrogenic Diabetes Insipidus
Primary: 24h Urine Volume — 6475; 4178; 6652; 4188 urine volume in mL/d
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
Diabetes Mellitus, Type 1 · Nephropathy · Diabetic Nephropathies
Primary: Copeptin Levels — 8.3 pmol/L
N/A N=21 Insulin and Polycystic Ovary Syndrome
PCOS
Primary: Renal Clearance of D-chiroinositol (DCI) at 12 Days — 4.75; 5.16 ml/min
Phase 4 N=24 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes
Prediabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance
Primary: Fasting Glucose — 5.1; 5.9 mmol/L — p=0.005
Phase 3 N=24 Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion
Metabolic Syndrome X
Primary: Waist Circumference at Week 12. — 97.6; 97.2 centimeters — p=<0.001
Phase 4 N=36 The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Type 2 Diabetes
Primary: Percent Change in Fractional Excretion of Sodium (FENA) — 41; -5.0 percentage of change — p==0.012
Phase 2 N=30 Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Cognitive Outcome: Brief Visuospatial Spatial Memory Test -Total Recall (Unit T Score) — 39.46; 41.23; 43.1; 50.9 T-score
Phase 2 N=34 Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
Diabetic Nephropathy
Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12 — -24.927; -20.563; -17.447 percent change
Phase 4 N=44 Renoprotective Effects of Dapagliflozin in Type 2 Diabetes
Diabetes Mellitus, Type 2 · Diabetic Nephropathies
Primary: Glomerular Filtration Rate (GFR) in ml/Min — 104; 109 ml/min
Phase 4 N=16 Renal and Hormonal Effects of Pioglitazone
Diabetes · Hypertension
Primary: Effects of Pioglitazone on Renal Hemodynamics — 68.0; 62.4 ml/min/1.73m2
Phase 2 N=244 Memory Aid by Intranasal Insulin in Diabetes (MemAID)
Type 2 Diabetes Mellitus
Primary: Gait Speed Normal Walk (cm/s). — 112.23; 103.42; 121.58; 119.51 cm/s — p=0.025
N/A N=18 Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
Insulin Sensitivity · Multiple Mitochondrial Dysfunctions Syndrome
Primary: Change in Insulin Sensitivity — 3.18; 3.85; 3.57; 5.22 mg/kg.min per µU/ml
Phase 3 N=251 Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
End Stage Renal Disease (ESRD) · Diabetes · CAPD
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
Phase 4 N=100 Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
Type II Diabetes
Primary: Change in 24-hour Mean Weighted Glucose (MWG) From Baseline to End of Treatment (Week 4) Using the Continuous Glucose Monitoring (CGM) System — -18.2; 5.8 mg/dL — p=<0.001
Phase 3 N=451 Dapagliflozin DPPIV Inhibitor add-on Study
Type 2 Diabetes
Primary: Adjusted Mean Change in HbA1c Levels — 0.04; -0.45 Percent — p=<0.0001
Phase 4 N=176 Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.
Type 2 Diabetes Mellitus
Primary: Hospital Length of Stay — 2.7; 3.1 days — p=0.58
Phase 1 N=48 Desmopressin Acetate 0.2 mg Tablets, Fasting
Healthy
Primary: Cmax - Maximum Observed Concentration — 78.102; 82.888 pg/mL
Phase 4 N=32 Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Adjusted Change From Baseline in Skeletal Muscle Insulin-stimulated Gluocose Uptake — 0.28; 0.28 umol/min/kg — p=0.9984
Phase 3 N=833 Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Adjusted Mean Change in HbA1c From Baseline at Week 24 — -0.45; -0.47; -0.03 Percentage of hemoglobin — p=<0.0001
Phase 3 N=813 Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Adjusted Mean Change From Baseline in HbA1c at Week 24 — -0.34; -0.39; 0.03 HbA1c (%) — p=<0.0001
Phase 2 N=10 The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
Cystinuria
Primary: 24hr Urine Measurements of the Effect of SGLT-2 Inhibitor Therapy on Cystine Production in Urine in Patients With Cystinuria — 999.3 24hr urine cystine concentration…
Phase 2 N=44 Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Adjusted Mean Percent Change From Baseline in Insulin Sensitivity at Week 12 (Last Observation Carried Forward [LOCF]) — -9.99; 7.98 % Change of Baseline Insulin…
Phase 4 N=85 Inpatient Diabetes on Corticosteroids
Diabetes Mellitus
Primary: Mean POC Glucose Level Between Groups — 225; 266 mg/dl
Phase 4 N=21 U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod
Type 2 Diabetes · Insulin Resistance
Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage
N/A N=17 Insulin Secretion in Diabetes Before and After Glycemic Control
Diabetes · Hyperglycemia
Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min
Phase 3 N=2,053 Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes
Diabetes, Type 1 · Diabetes, Type 2
Primary: Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care — -0.16; -0.12 liters
Phase 2 N=30 Diabetes in Neuropsychiatric Disorders
Schizophrenia
Primary: Body Mass Index — 22.1; 23.5; 24.2; 24.3 kg/m^2 — p=<0.001
N/A N=20 Cerebral Edema in Pediatric Diabetic Ketoacidosis
Diabetic Ketoacidosis
Primary: Cerebral Edema Measured by MR Imaging (Apparent Diffusion Coefficient) — 36; 48 mm^2/sec
Phase 2 N=46 Dapagliflozin In Alzheimer's Disease
Alzheimer Disease
Primary: Ratio of Cerebral N Acetyl-Aspartate (NAA) / Cerebral Creatine — 1.49; 1.42 Ratio
Phase 4 N=47 Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension
Hypertension
Primary: Sympathetic Nerve Activity — 46; 40; 49; 42 bursts/min